| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05254743) | Loxo Oncology, Inc. | 2022-07-22 |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) (NCT05458297) | Merck Sharp & Dohme LLC | 2022-07-21 |
| Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma (NCT05037669) | University of Pennsylvania | 2022-07-01 |
| In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia) (NCT04785989) | University of Wisconsin, Madison | 2022-06-13 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT05410041) | Beijing Boren Hospital | 2022-05-25 |
| Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk (NCT06475469) | CHU de Reims | 2022-05-10 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572) | Newave Pharmaceutical Inc | 2022-05-08 |
| Early Intervention With Acalabrutinib in Patients With High Risk CLL (NCT04660045) | Weill Medical College of Cornell University | 2022-05-01 |
| Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (NCT05326308) | iOMEDICO AG | 2022-04-26 |
| A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL (NCT05197192) | German CLL Study Group | 2022-04-19 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (NCT05287984) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-22 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (NCT05246345) | University Hospital, Clermont-Ferrand | 2022-03-07 |
| Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers (NCT04844528) | University of Utah | 2022-02-25 |
| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy (NCT06782854) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-02-21 |
| Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (NCT05183854) | University of Utah | 2022-01-31 |
| Financial Difficulty in Patients With Blood Cancer (NCT05212233) | UNC Lineberger Comprehensive Cancer Center | 2022-01-27 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL (NCT05147467) | Ascentage Pharma Group Inc. | 2021-12-28 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome (NCT04978779) | Vincerx Pharma, Inc. | 2021-12-16 |
| Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL (NCT04908228) | Paolo Ghia | 2021-12-13 |
| CLL Therapy Approaches in Russia (NCT05140369) | AstraZeneca | 2021-10-29 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Study on the Diagnosis and Management of CLL in Italy by GIMEMA (NCT04867915) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-10-13 |
| MEOI and HRQoL in CLL Patients Treated With BTKis (NCT04938141) | AstraZeneca | 2021-10-07 |
| Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia (NCT05093192) | University of Bath | 2021-10-01 |
| Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients (NCT04640909) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-10-01 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (NCT04904588) | Center for International Blood and Marrow Transplant Research | 2021-09-30 |
| Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation (NCT04679012) | Weill Medical College of Cornell University | 2021-09-24 |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05023980) | Loxo Oncology, Inc. | 2021-09-23 |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT04965493) | Loxo Oncology, Inc. | 2021-09-20 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (NCT04809467) | Incyte Corporation | 2021-09-16 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation (NCT04980859) | Nanfang Hospital, Southern Medical University | 2021-09-01 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678) | Nkarta, Inc. | 2021-08-20 |
| COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies (NCT05028374) | Barbara Ann Karmanos Cancer Institute | 2021-08-17 |
| FT819 in Subjects With B-cell Malignancies (NCT04629729) | Fate Therapeutics | 2021-07-12 |
| Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML (NCT04887259) | Lava Therapeutics | 2021-07-12 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL (NCT04722172) | Memorial Sloan Kettering Cancer Center | 2021-05-21 |
| A Study of FCN-338 in Patients With Chronic CLL/SLL (NCT04682808) | Fochon Pharmaceuticals, Ltd. | 2021-05-13 |
| huCART19-IL18 in CD19+ Cancers (NCT04684563) | University of Pennsylvania | 2021-05-06 |
| Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients (NCT04691765) | Dr. David Spaner | 2021-05-01 |
| Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies (NCT04732845) | Benjamin Tomlinson | 2021-04-26 |
| Safe Accelerated Venetoclax Escalation in CLL (NCT04843904) | Dana-Farber Cancer Institute | 2021-04-14 |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies (NCT04796675) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-04-10 |
| Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications (NCT04595851) | University of Michigan Rogel Cancer Center | 2021-03-26 |
| Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors (NCT04814004) | Kai Lin Xu; Jun Nian Zheng | 2021-03-19 |
| Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04852822) | University of Washington | 2021-03-18 |
| Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia (NCT04657094) | City of Hope Medical Center | 2021-03-16 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902) | National Cancer Institute (NCI) | 2021-03-02 |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (NCT04419389) | Aprea Therapeutics | 2021-03-02 |
| A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NCT04657224) | Janssen Research & Development, LLC | 2021-02-25 |
| Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL (NCT04502394) | Kartos Therapeutics, Inc. | 2021-02-23 |
| Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies (NCT04504708) | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | 2021-02-17 |
| Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy (NCT04149821) | Weill Medical College of Cornell University | 2021-02-10 |
| ALICIA (Acalabrutinib in CLL Therapy) (NCT04746950) | AstraZeneca | 2021-02-03 |
| Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL (NCT04862806) | Bnai Zion Medical Center | 2021-02-01 |
| ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL (NCT04578613) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-01-08 |
| MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies (NCT04370457) | Centre for Research and Technology Hellas | 2021-01-01 |
| Personalized Multi-peptide Vaccination in CLL Patients (NCT04688385) | University Hospital Tuebingen | 2020-12-23 |
| A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT04694560) | Memorial Sloan Kettering Cancer Center | 2020-12-22 |
| Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT (NCT05928156) | Duke University | 2020-12-17 |
| Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia (NCT04512105) | University of California, Irvine | 2020-12-02 |
| Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) (NCT04665115) | Academic and Community Cancer Research United | 2020-11-23 |
| Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL (NCT04560322) | Massachusetts General Hospital | 2020-10-19 |
| The clonoSEQ® Watch Registry (NCT04545333) | Adaptive Biotechnologies | 2020-10-13 |
| Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) (NCT04502030) | Octapharma | 2020-10-05 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (NCT03639324) | Virginia Commonwealth University | 2020-10-02 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (NCT04553692) | IGM Biosciences, Inc. | 2020-09-23 |
| Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma (NCT04189952) | University of Miami | 2020-09-22 |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (NCT04312841) | Ohio State University Comprehensive Cancer Center | 2020-09-15 |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (NCT04240704) | Novartis Pharmaceuticals | 2020-09-07 |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia (NCT04505254) | M.D. Anderson Cancer Center | 2020-08-25 |
| Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (NCT04501939) | University of California, San Diego | 2020-08-06 |
| Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy (NCT04282811) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-07-24 |
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers (NCT04464200) | Memorial Sloan Kettering Cancer Center | 2020-07-06 |
| Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia (NCT04616274) | National Taiwan University Hospital | 2020-07-01 |
| A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma (NCT04356846) | The First Affiliated Hospital with Nanjing Medical University | 2020-05-01 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (NCT04342117) | SecuraBio | 2020-04-23 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (NCT04018248) | Boryung Pharmaceutical Co., Ltd | 2020-04-21 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL (NCT04030195) | Precision BioSciences, Inc. | 2020-03-24 |
| FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies (NCT04245722) | Fate Therapeutics | 2020-03-19 |
| Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia (NCT04774744) | M.D. Anderson Cancer Center | 2020-03-17 |
| Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance (NCT03943342) | Kerry Rogers | 2020-03-11 |
| DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer (NCT04282343) | Barbara Ann Karmanos Cancer Institute | 2020-02-25 |
| Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL (NCT04155710) | Iovance Biotherapeutics, Inc. | 2020-02-19 |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies (NCT04043845) | Dana-Farber Cancer Institute | 2020-02-03 |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04155840) | University of Washington | 2020-01-31 |
| A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece (NCT04159779) | AbbVie | 2020-01-13 |
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma (NCT04160195) | National Cancer Institute (NCI) | 2019-12-20 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) (NCT04163718) | H. Lee Moffitt Cancer Center and Research Institute | 2019-11-12 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma (NCT03892044) | David Bond, MD | 2019-11-05 |
| CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (NCT03765177) | Ottawa Hospital Research Institute | 2019-10-16 |